EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma



A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma



Journal of Asthma 46(5): 465-469



Loratadine added to montelukast has been suggested to improve endpoints of asthma. This study investigated the additive effects of concomitant montelukast and loratadine when compared with montelukast, loratadine, and inhaled beclomethasone monotherapies in asthma. Methods. Patients (N = 406) were 15 to 65 years of age with a forced expiratory volume in 1 second (FEV(1))-predicted of 50% to 85%, FEV(1) reversibility > or = 15%, and a minimal level of daytime symptoms and beta -agonist use. This three-part 2X2 crossover-study consisted of two double-blind 6-week treatment periods where patients were administered once daily oral montelukast 10 mg, loratadine 10 mg, montelukast 10 mg + loratadine 10 mg, or twice daily inhaled beclomethasone 200 mu g. A subsequent 48-week extension study compared montelukast + loratadine with beclomethasone. The primary endpoint was the percentage change from baseline in FEV(1). Over 6 weeks of double-blind treatment, significant improvements (p < 0.05) in the primary endpoint of FEV(1) were seen for montelukast + loratadine versus loratadine (least-square mean percentage-point difference of 5.8%), beclomethasone versus montelukast + loratadine (2.35%), montelukast versus loratadine (5.94%), and beclomethasone versus montelukast (4.65%); a numerical improvement (p = 0.054) was seen for montelukast + loratadine versus montelukast (1.60%). Significant improvements for montelukast + loratadine versus montelukast were seen in some secondary endpoints (evening peak expiratory flow, nocturnal asthma symptom score, nocturnal awakenings, and asthma-specific quality of life) but not others. Significant improvements in most endpoints except daytime asthma symptoms score were seen for montelukast + loratadine versus loratadine. In the extension study, both montelukast + loratadine and beclomethasone improved several endpoints. All treatments were generally comparable in the percentage of patients with clinical and laboratory adverse experiences. In this study, the addition of loratadine to montelukast produced a small numerical, but not statistically significant, improvement in FEV(1) and, in general, no consistent improvement in other asthma endpoints. No improvement of montelukast + loratadine versus beclomethasone was seen in any endpoint.

(PDF emailed within 0-6 h: $19.90)

Accession: 051229329

Download citation: RISBibTeXText

PMID: 19544166

DOI: 10.1080/02770900902846323



Related references

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Annals of Internal Medicine 130(6): 487-495, 1999

Effects of montelukast , loratadine, montelukast + loratadine and placebo in seasonal allergic rhinitis and conjunctivitis. Journal of Allergy & Clinical Immunology 101(1 PART 2): S97, 1998

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. American Journal of Respiratory and Critical Care Medicine 160(6): 1862-1868, 1999

Concomitant montelukast and loratadine provide rapid significant improvement in seasonal allergic rhinitis compared with loratadine alone. European Respiratory Journal 12(SUPPL 28): 274S, Sept, 1998

Efficacy of prophylactic treatment with montelukast and montelukast plus add-on loratadine for seasonal allergic rhinitis. Allergy and Asthma Proceedings 33(2): E17-E22, 2012

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 279(15): 1181-1186, 1998

Treatment of allergic asthma with loratadine and salmeterol versus montelukast. Allergy (Copenhagen) 56(Supplement 68): 99, 2001

Treatment of fall allergic rhinitis with montelukast alone or in combination with loratadine in a multicenter, double-blind, randomized, placebo-controlled study. Journal of Allergy & Clinical Immunology 107(2): S158, February, 2001

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Archives of Internal Medicine 158(11): 1213-1220, 1998

Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respiratory Medicine 104(5): 644-651, 2010

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. Journal of Allergy and Clinical Immunology 105(5): 917-922, 2000

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial. Annals of Internal Medicine 130(6): 487-495, March 16, 1999

Improvement in rhinoconjunctivitis quality of life outcomes in the treatment of fall allergic rhinitis by montelukast alone or in combination with loratadine in a multicenter, double-blind, randomized, placebo-controlled study. Journal of Allergy & Clinical Immunology 107(2): S158, February, 2001

Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. European Respiratory Journal 11(6): 1232-1239, 1998

Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Archives of Internal Medicine 160(16): 2481-2488, 2000